Azienda Ospedaliera di Perugia
- Address
- lock Available on a paid plan
Immune System Diseases
The Azienda Ospedaliera di Perugia Neurofisiopatologia unit is investigating targeted treatments for IgA nephropathy, an immune‑mediated kidney disorder. The study evaluates early corticosteroid intervention and novel SGLT2 inhibitor regimens to affect disease progression.
- Assess early corticosteroid therapy based on biopsy findings
- Compare SGLT2 inhibitor (Dapagliflozin) plus RAS blockade versus standard steroid‑RAS approach
- Measure impact on proteinuria and renal function
- Explore personalized treatment strategies for active versus chronic lesions
Findings could influence future care at Azienda Ospedaliera di Perugia by providing safer alternatives to high‑dose steroids.
Musculoskeletal Diseases
The Neurofisiopatologia department is conducting a trial on amyotrophic lateral sclerosis, a progressive neuromuscular disease. Researchers are evaluating whether acetyl‑L‑carnitine can slow functional decline and preserve independence.
- Test two dosage levels of acetyl‑L‑carnitine
- Monitor changes in the ALSFRS‑R functional rating scale
- Assess safety and tolerability in ALS patients
- Determine potential to delay loss of self‑sufficiency
Positive outcomes may expand therapeutic options for ALS patients treated at Azienda Ospedaliera di Perugia.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliera di Perugia
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Corticosteroids, Dapagliflozin, and RASBs on Proteinuria in IgA Nephropathy Patients with Active and Chronic Renal Lesions | Fondazione Schena Centro Europeo Della Ricerca Sulle Malattie Renali | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| ACETYLCARNITINE HYDROCHLORIDE | 1 | Unknown | 2025-02-24 | 2025-02-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.